Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes

Background: Angiogenin, an enzyme belonging to the ribonucleases A superfamily, plays an important role in vascular biology. Here, we sought to study the association of plasma angiogenin and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes (T2D). Methods: This prospective...

Full description

Saved in:
Bibliographic Details
Main Authors: Gurung, Resham L., Liu, Sylvia, Liu, Jian-Jun, Yiamunaa, M., Zheng, Huili, Chan, Clara, Ang, Keven, Subramaniam, Tavintharan, Sum, Chee Fang, Lim, Su Chi
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2024
Subjects:
Online Access:https://hdl.handle.net/10356/174969
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-174969
record_format dspace
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Medicine, Health and Life Sciences
Angiogenin
Major adverse cardiovascular events
spellingShingle Medicine, Health and Life Sciences
Angiogenin
Major adverse cardiovascular events
Gurung, Resham L.
Liu, Sylvia
Liu, Jian-Jun
Yiamunaa, M.
Zheng, Huili
Chan, Clara
Ang, Keven
Subramaniam, Tavintharan
Sum, Chee Fang
Lim, Su Chi
Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
description Background: Angiogenin, an enzyme belonging to the ribonucleases A superfamily, plays an important role in vascular biology. Here, we sought to study the association of plasma angiogenin and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes (T2D). Methods: This prospective study included 1083 T2D individuals recruited from a secondary hospital and a primary care facility. The primary outcome was a composite of four-point MACE (nonfatal myocardial infarction, stroke, unstable angina pectoris leading to hospitalization and cardiovascular death). Circulating angiogenin was measured by a proximity extension assay. Cox regression models were used to evaluate the association of baseline plasma angiogenin with the risk of MACE. Results: During a median follow-up of 9.3 years, 109 (10%) MACE were identified. Plasma angiogenin was significantly higher in participants with MACE than in those without MACE (P < 0.001). Doubling of plasma angiogenin concentration was associated with a 3.10-fold (95% CI 1.84–5.22) increased risk for MACE. The association was only moderately attenuated after adjustment for demographic and cardiometabolic risk factors (adjusted HR 2.38, 95% CI 1.34–4.23) and remained statistically significant after additional adjustment for estimated glomerular filtration rate (eGFR) and urinary albumin to creatinine ratio (uACR) (adjusted HR 1.90, 95% CI 1.02–3.53). A consistent outcome was obtained when plasma angiogenin was analysed as a categorical variable in tertiles. Conclusions: Plasma angiogenin was associated with the risk of future cardiovascular events in patients with T2D and may be a promising novel biomarker for identifying high-risk T2D patients for early management.
author2 Lee Kong Chian School of Medicine (LKCMedicine)
author_facet Lee Kong Chian School of Medicine (LKCMedicine)
Gurung, Resham L.
Liu, Sylvia
Liu, Jian-Jun
Yiamunaa, M.
Zheng, Huili
Chan, Clara
Ang, Keven
Subramaniam, Tavintharan
Sum, Chee Fang
Lim, Su Chi
format Article
author Gurung, Resham L.
Liu, Sylvia
Liu, Jian-Jun
Yiamunaa, M.
Zheng, Huili
Chan, Clara
Ang, Keven
Subramaniam, Tavintharan
Sum, Chee Fang
Lim, Su Chi
author_sort Gurung, Resham L.
title Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
title_short Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
title_full Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
title_fullStr Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
title_full_unstemmed Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
title_sort association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
publishDate 2024
url https://hdl.handle.net/10356/174969
_version_ 1814047053411516416
spelling sg-ntu-dr.10356-1749692024-04-21T15:41:18Z Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes Gurung, Resham L. Liu, Sylvia Liu, Jian-Jun Yiamunaa, M. Zheng, Huili Chan, Clara Ang, Keven Subramaniam, Tavintharan Sum, Chee Fang Lim, Su Chi Lee Kong Chian School of Medicine (LKCMedicine) Khoo Teck Puat Hospital, Admiralty Medical Centre Saw Swee Hock School of Public Heath Duke-NUS Medical School Medicine, Health and Life Sciences Angiogenin Major adverse cardiovascular events Background: Angiogenin, an enzyme belonging to the ribonucleases A superfamily, plays an important role in vascular biology. Here, we sought to study the association of plasma angiogenin and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes (T2D). Methods: This prospective study included 1083 T2D individuals recruited from a secondary hospital and a primary care facility. The primary outcome was a composite of four-point MACE (nonfatal myocardial infarction, stroke, unstable angina pectoris leading to hospitalization and cardiovascular death). Circulating angiogenin was measured by a proximity extension assay. Cox regression models were used to evaluate the association of baseline plasma angiogenin with the risk of MACE. Results: During a median follow-up of 9.3 years, 109 (10%) MACE were identified. Plasma angiogenin was significantly higher in participants with MACE than in those without MACE (P < 0.001). Doubling of plasma angiogenin concentration was associated with a 3.10-fold (95% CI 1.84–5.22) increased risk for MACE. The association was only moderately attenuated after adjustment for demographic and cardiometabolic risk factors (adjusted HR 2.38, 95% CI 1.34–4.23) and remained statistically significant after additional adjustment for estimated glomerular filtration rate (eGFR) and urinary albumin to creatinine ratio (uACR) (adjusted HR 1.90, 95% CI 1.02–3.53). A consistent outcome was obtained when plasma angiogenin was analysed as a categorical variable in tertiles. Conclusions: Plasma angiogenin was associated with the risk of future cardiovascular events in patients with T2D and may be a promising novel biomarker for identifying high-risk T2D patients for early management. National Medical Research Council (NMRC) Published version This work was funded by Singapore National Medical Research Council Grants (MOH-00066, MOH-000714-01 and MOH-001327-02) and Khoo Teck Puat Hospital Science Translational and Applied Research (STAR) grants (20201, 21109 and 23201). The funder has no role in the study design, data analysis, manuscript writing or decision to submit for publication. 2024-04-17T06:55:25Z 2024-04-17T06:55:25Z 2024 Journal Article Gurung, R. L., Liu, S., Liu, J., Yiamunaa, M., Zheng, H., Chan, C., Ang, K., Subramaniam, T., Sum, C. F. & Lim, S. C. (2024). Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes. Cardiovascular Diabetology, 23(1), 70-. https://dx.doi.org/10.1186/s12933-024-02156-8 1475-2840 https://hdl.handle.net/10356/174969 10.1186/s12933-024-02156-8 38360721 2-s2.0-85185241542 1 23 70 en MOH-00066 MOH-000714–01 MOH-001327-02 20201 21109 23201 Cardiovascular Diabetology © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. application/pdf